Preethi Jeyaraman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Preethi Jeyaraman has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Rahul Naithani
Division of Hematology and Bone Marrow Transplant, Max Super-speciality Hospital, India
6 shared publicationsNitin Dayal
Department of Lab Medicine Max Superspecialty Hospital Delhi India
5 shared publicationsPronamee Borah
Hematology and Bone Marrow Transplant Paras Health Gurugram India
4 shared publications- Rahul Naithani
Department of Hematology and Bone Marrow Transplant, Artemis Hospital, Gurugram, Haryana, India
4 shared publications Sangeeta Pathak
Department of Transfusion Medicine, Max Super-speciality Hospital, India
2 shared publications- Akhilesh Singh
CSIR-CDRI, Lucknow, India
1 shared publication
Latest Publications
- 7 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31654
A Novel Mutation in the Adenosine Deaminase‐2 Gene Presenting as Severe Chronic Neutropenia With Myeloid Hypoplasia
- 7 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31654
A Novel Mutation in the Adenosine Deaminase‐2 Gene Presenting as Severe Chronic Neutropenia With Myeloid Hypoplasia
- 1 May 2021
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 88, 102464
Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia
- 1 May 2021
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 88, 102464
Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia
- Open Access
- 1 April 2020
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (2) , 227-228
Alternative Strategies in Thalassemia: Focus on Thalidomide
- 1 April 2020
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (2) , 227-228
Open AccessAlternative Strategies in Thalassemia: Focus on Thalidomide
- Open Access
- 31 March 2020
- Published by Springer Nature in Blood Research
- Vol. 55 (1) , 65-67
Daratumumab in dialysis-dependent multiple myeloma
- 31 March 2020
- Published by Springer Nature in Blood Research
- Vol. 55 (1) , 65-67
Open AccessDaratumumab in dialysis-dependent multiple myeloma
- 1 March 2020
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 81, 102400
Thrombotic microangiopathy after carfilzomib in a very young myeloma patient
- 1 March 2020
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 81, 102400
Thrombotic microangiopathy after carfilzomib in a very young myeloma patient
- 29 October 2019
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 42 (1) , e64-e65
Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) has different disease biology with a more aggressive clinical course in children. Achieving treatment-free remission is the ideal goal for the pediatric CML population to avoid long-term toxicities of tyrosine kinase inhibitors. Here, we present our experience of stopping Imatinib in a pediatric patient of CML who had excessive weight gain with Imatinib. He is currently maintaining treatment-free remission for 15 months after stopping therapy at the time of last follow-up. The patient also had normalization of body mass index with the stopping of Imatinib.
- 29 October 2019
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 42 (1) , e64-e65
Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) has different disease biology with a more aggressive clinical course in children. Achieving treatment-free remission is the ideal goal for the pediatric CML population to avoid long-term toxicities of tyrosine kinase inhibitors. Here, we present our experience of stopping Imatinib in a pediatric patient of CML who had excessive weight gain with Imatinib. He is currently maintaining treatment-free remission for 15 months after stopping therapy at the time of last follow-up. The patient also had normalization of body mass index with the stopping of Imatinib.
- 28 October 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (2) , 419-421
Primary Cardiac Lymphoma
- 28 October 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (2) , 419-421
Primary Cardiac Lymphoma
- 4 October 2019
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 42 (7) , e670-e672
Hematogone Hyperplasia Masquerading as Acute Lymphoblastic Leukemia With Concurrent Hypercupremia
Alterations in copper homeostasis is an uncommon cause for hematological alterations frequently presenting with dysplastic features in the bone marrow. Most of these alterations have been documented in adult patients with copper deficiency. Rare cases show hematogone hyperplasia in these patients. Effects of mild copper excess have not been documented in literature. We are describing a pediatric patient who presented with pancytopenia associated with hypercupraemia (excess of copper). Bone marrow examination showed hematogone hyperplasia. Interestingly, correction of serum copper levels with zinc therapy lead to complete improvement in pancytopenia. Hematogones had also reduced in subsequent marrow biopsy after therapy.
- 4 October 2019
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 42 (7) , e670-e672
Hematogone Hyperplasia Masquerading as Acute Lymphoblastic Leukemia With Concurrent Hypercupremia
Alterations in copper homeostasis is an uncommon cause for hematological alterations frequently presenting with dysplastic features in the bone marrow. Most of these alterations have been documented in adult patients with copper deficiency. Rare cases show hematogone hyperplasia in these patients. Effects of mild copper excess have not been documented in literature. We are describing a pediatric patient who presented with pancytopenia associated with hypercupraemia (excess of copper). Bone marrow examination showed hematogone hyperplasia. Interestingly, correction of serum copper levels with zinc therapy lead to complete improvement in pancytopenia. Hematogones had also reduced in subsequent marrow biopsy after therapy.
- 1 August 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (1) , 200-201
Hypercalcemia Related Pancreatitis in a Patient with Multiple Myeloma
- 1 August 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (1) , 200-201
Hypercalcemia Related Pancreatitis in a Patient with Multiple Myeloma
- Open Access
- 14 January 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 35 (1) , 12-16
Highlights of Abstracts on Hematopoietic Stem Cell Transplant in Annual Conference of ISHBT 2018
Stem cell transplant in India has been seeing a steady progressive growth over the last decade. Thirty abstracts related to various aspects of bone marrow transplant were presented in the annual conference of Indian Society of Hematology and Transfusion medicine in 2018. All abstracts which were published were reviewed. They were categorized into autologous transplants, allogeneic transplants, lab aspects and supportive care. They have been summarized to provide a snapshot of the data presented. These data are likely to encourage to start or enhance transplant activity at other centers.
- 14 January 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 35 (1) , 12-16
Open AccessHighlights of Abstracts on Hematopoietic Stem Cell Transplant in Annual Conference of ISHBT 2018
Stem cell transplant in India has been seeing a steady progressive growth over the last decade. Thirty abstracts related to various aspects of bone marrow transplant were presented in the annual conference of Indian Society of Hematology and Transfusion medicine in 2018. All abstracts which were published were reviewed. They were categorized into autologous transplants, allogeneic transplants, lab aspects and supportive care. They have been summarized to provide a snapshot of the data presented. These data are likely to encourage to start or enhance transplant activity at other centers.